Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Glucagon-like peptide-1 (GLP-1) is a growth and differentiation factor for mature β-cells and their precursors. However, the overall effect of GLP-1 on increasing β-cell mass in both in vivo and in vitro conditions is relatively small, and augmenting this effect would be beneficial for the treatment or prevention of type 1 and type 2 diabetes. Here, we searched for cellular mechanisms that may limit the proliferative effect of GLP-1 and tested whether blocking them could increase β-cell proliferation. RESEARCH DESIGN AND METHODS—We examined GLP-1–regulated genes in βTC-Tet cells by cDNA microarrays. To assess the effect of some of these gene on cell proliferation, we reduced their expression using small heterogenous RNA in β-cell lines and primary mouse islets and measured [3H]thymidine or 5′-bromo-2′-deoxyuridine incorporation. RESULTS—We identified four negative regulators of intracellular signaling that were rapidly and strongly activated by GLP-1: the regulator of G-protein–signaling RGS2; the cAMP response element-binding protein (CREB) antagonists cAMP response element modulator (CREM)-α and ICERI; and the dual specificity phosphatase DUSP14, a negative regulator of the mitogen-activated protein kinase (MAPK)/extracellular signal–regulated kinase 1/2 (ERK1/2) pathway. We show that knockdown of CREMα or DUSP14 or expression of a dominant-negative form of DUSP14 increased β-cell line proliferation and enhanced the GLP-1–induced proliferation of primary β-cells. CONCLUSIONS—Together, our data show that 1) the cAMP/protein kinase A/CREB and MAPK/ERK1/2 pathways can additively control β-cell proliferation, 2) β-cells have evolved several mechanisms limiting GLP-1–induced cellular proliferation, and 3) blocking these mechanisms increases the positive effect of GLP-1 on β-cell mass.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An analogous strategy, i.e. the inhibition of an inhibitor, has been used recently as a solution to enhance β-cell proliferation by attenuating signals that restrain GLP-1 action [72].”
From Expansion of β-cell mass in response to pregnancy (2010) · cites this paper as [72]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 4×
“P values were adjusted for multiple testing using the false discovery rate method proposed by Benjamini and Hochberg (24).”
MethodInfluentialA System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291 · cited 4×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluentialβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation
Dor, Y., Brown, J., Martinez, O. I., & Melton, D. A. (2004) · Nature · doi:10.1038/nature02520 · Cited by 2,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Increasing the mass of existing -cells by interfering with the mechanisms we have described here could be used to improve GLP-1–based therapy of type 2 diabetes (47,48) so long as reducing the expression of these negative regulators could be finely tuned so as not to overcome the natural feedback loops that normally p…”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Increasing the mass of existing -cells by interfering with the mechanisms we have described here could be used to improve GLP-1–based therapy of type 2 diabetes (47,48) so long as reducing the expression of these negative regulators could be finely tuned so as not to overcome the natural feedback loops that normally p…”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 4×
“The -cell GLP-1 receptor is a Gs-protein–coupled receptor (16) that activates the cAMP/protein kinase A (PKA)/cAMP response element-binding protein (CREB) pathway (17) but also the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (18,19) by a mechanism that involves ac…”
BackgroundMethodSelf-citationWiznerowicz, M., & Trono, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8957-8951.2003 · Cited by 701 · cited 4×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluential
Cited by
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Dual-specificity phosphatases: critical regulators with diverse cellular targets
Patterson, K. I., Brummer, T., O'brien, P. M., & Daly, R. J. (2009) · Biochemical Journal · doi:10.1042/bj20082234 · Cited by 744
Expansion of β-cell mass in response to pregnancy
Rieck, S., & Kaestner, K. H. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.001 · Cited by 358
Agrawal, N., Delanoue, R., Mauri, A., Basco, D., Pasco, M., Thorens, B., & Léopold, P. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.003 · Cited by 206
“Real-time quantitative PCR was performed in a 20 ml reaction mixture including 13QuantiTectTM SYBRGreen PCR Master Mix (QIAGEN) and 10 pmol of each primer, as described (Klinger et al., 2008).”
MethodSelf-citationQuoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert, J., Bertrand, G., & Dalle, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067207 · Cited by 187
Cornu, M., Yang, J.-Y., Jaccard, E., Poussin, C., Widmann, C., & Thorens, B. (2009) · Diabetes · doi:10.2337/db09-0063 · Cited by 146
“Western blot analysis was performed as described (21) with antibodies diluted in Tris-buffered saline–5% nonfat dry milk (1/500 dilution for IGF-1R, IR and phosphorylated Akt [Thr308 and Ser473], and phosphorylated Bad and 1/1,000 for actin, total Akt, total Bad, and IGF-2) and revealed using horseradish peroxidase–co…”
MethodResultInfluentialSelf-citationSanz, C., Vázquez, P., Blázquez, C., Barrio, P. A., Alvarez, M. D. M., & Blázquez, E. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2009 · Cited by 135
Drug Delivery System in the Treatment of Diabetes Mellitus
Zhao, R., Lü, Z., Yang, J., Zhang, L., Li, Y., & Zhang, X. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00880 · Cited by 122
Koole, C., Wootten, D. L., Simms, J., Valant, C., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072884 · Cited by 106
Cyclic AMP Signaling in Pancreatic Islets
Furman, B. L., Ong, W. K., & Pyne, N. J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_13 · Cited by 109
Vidal, J., Nicolau, J., Romero, F., Casamitjana, R., Momblan, D., Conget, I., Morínigo, R., & Lacy, A. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1620 · Cited by 94
Cornu, M., Modi, H., Kawamori, D., Kulkarni, R. N., Joffraud, M., & Thorens, B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091116 · Cited by 92
Self-citationKoole, C., Wootten, D., Simms, J., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.309328 · Cited by 87
Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
Dual-Specificity Phosphatases as Molecular Targets for Inhibition in Human Disease
Ríos, P., Nunes‐Xavier, C. E., Tabernero, L., Köhn, M., & Pulido, R. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5709 · Cited by 97
“In addition, a negative role was demonstrated for DUSP14 in the proliferation and maturation of rat pancreatic b -cells in response to glucagon-like peptide 1, suggesting that DUSP14 inhibition could be beneficial to increase pancreatic b -cell mass in type 1 diabetes (97).”
Rajan, S., Dickson, L. M., Mathew, E., Orr, C. M. O., Ellenbroek, J. H., Philipson, L. H., & Wicksteed, B. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.010 · Cited by 77
Roger, B., Papin, J., Vacher, P., Raoux, M., Mulot, A., Dubois, M., Kerr-Conte, J. A., Voy, B. H., Pattou, F. N., Charpentier, G., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1955-x · Cited by 89
Yang, C., Li, J., Chiu, L., Lan, J., Chen, D., Chuang, H., Huang, C., & Tan, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300989 · Cited by 81
“DUSP14 dominant–negative mutant enhances pancreatic b cell proliferation by increasing ERK activation in the overexpressing system (6).”
BackgroundNeomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas
Cromer, M. K., Choi, M., Nelson-Williams, C. J., Fonseca, A. L., Kunstman, J. W., Korah, R. M., Overton, J. D., Mane, S., Kenney, B. C., Malchoff, C. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503696112 · Cited by 76
Li, C., Zhou, Q., Yang, L.-C., Chen, Y.-H., Hou, J., Guo, K., Wang, Y., & Li, Y. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0536-7 · Cited by 68
“b-cells expressing dominant-negative Dusp14 showed an increased rate of proliferation accompanied by increased ERK activation [17].”
BackgroundShin, S., Le Lay, J., Everett, L. J., Gupta, R., Rafiq, K., & Kaestner, K. H. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.08.001 · Cited by 62
Dalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Kalkman, H. O. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.008 · Cited by 66
Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver
Wang, S., Yan, Z., Yang, X., An, S., Zhang, K., Qi, Y., Zheng, J., Ji, Y., Wang, P., Fang, C., et al. (2017) · Hepatology · doi:10.1002/hep.29616 · Cited by 60
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Chon, S., & Gautier, J. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.2.99 · Cited by 66
Tordera, R. M., Garcia‐García, Á. L., Elizalde, N., Segura, V., Aso, E., Vénzala, E., Ramírez, M. J., & del Río, J. A. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.016 · Cited by 59
Regulation of beta cell replication
Lee, Y. C., & Nielsen, J. H. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.033 · Cited by 63
“Kim et al have shown that exendin-4, a GLP-1 receptor agonist, increased cyclin D1 expression in the pancreatic bet-cell line, INS-1, and acted predominantly via the cAMP/PKA signalling pathway (Kim et al., 2006).”
InfluentialLeach, K., Conigrave, A. D., Sexton, P. M., & Christopoulos, A. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.004 · Cited by 49
Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice
Yamamoto, T. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2512 · Cited by 48
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Modi, H., Cornu, M., & Thorens, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.587733 · Cited by 42
“The lysates were centrifuged for 15 min at 13,000 rpm at 4 °C, and the supernatant was used for Western blot analysis (26).”
MethodSelf-citationMokhtari, D., Al-Amin, R. A., Turpaev, K. T., Li, T., Idevall‐Hagren, O., Li, J., Wuttke, A., Fred, R. G., Ravassard, P., Scharfmann, R., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2868-2 · Cited by 37
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809046200 · Cited by 35
Lin, B., Xu, J., Feng, D., Wang, F., Wang, J., & Zhao, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.101 · Cited by 36
Akinci, M. A., Turner, H. C., Taveras, M., & Wolosin, J. M. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3791 · Cited by 35
TRAF2-mediated Lys63-linked ubiquitination of DUSP14/MKP6 is essential for its phosphatase activity
Yang, C., Chiu, L., & Tan, T. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.10.017 · Cited by 31
Repurposing cAMP-Modulating Medications to Promote β-Cell Replication
Zhao, Z., Low, Y., Armstrong, N., Kenty, J. H.-R., Sun, S. A., Arvanites, A. C., Hollister‐Lock, J., Shah, N. H., Weir, G. C., & Annes, J. P. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1120 · Cited by 30
Concise Review: In Search of Unlimited Sources of Functional Human Pancreatic Beta Cells
Scharfmann, R., Rachdi, L., & Ravassard, P. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0120 · Cited by 42
Li, Y., Fei, L., Wang, J., & Niu, Q. (2020) · Cardiovascular Engineering and Technology · doi:10.1007/s13239-019-00452-z · Cited by 26
Klf6 protects β-cells against insulin resistance-induced dedifferentiation
Dumayne, C., Tarussio, D., Sánchez-Archidona, A. R., Picard, A., Basco, D., Berney, X. P., Ibberson, M. R., & Thorens, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.02.001 · Cited by 28
Self-citationRegulator of G protein signaling 2 is a key regulator of pancreatic β-cell mass and function
Dong, H., Zhang, Y., Wang, J., Kim, D. S., Wu, H., Sjögren, B., Gao, W., Luttrell, L. M., & Wang, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.216 · Cited by 26
Hui, H., Tang, Y. G., Zhu, L., Khoury, N., Hui, J. Z., Wang, K. Y., Perfetti, R., & Go, V. L. W. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181bc30dd · Cited by 25
DUSP28 contributes to human hepatocellular carcinoma via regulation of the p38 MAPK signaling
Wang, D., Han, S., Peng, R., Jiao, C., Wang, X., Han, Z., & Li, X. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2653 · Cited by 28
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Vilsbøll, T., Holst, J. J., & Knop, F. K. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.011 · Cited by 25
Overproduction, purification and structure determination of human dual-specificity phosphatase 14
Lountos, G. T., Tropea, J. E., Cherry, S., & Waugh, D. S. (2009) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909023762 · Cited by 23
“DUSP14 has also been shown to contribute to the proliferation of pancreatic -cells by affecting ERK activity, which raises further questions as to the possible roles of DUSP14 in cellular growth, proliferation and differentiation in other cell types such as cancer (Klinger et al., 2008).”
BackgroundThe required beta cell research for improving treatment of type 2 diabetes
Thorens, B. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12096 · Cited by 26
Self-citationDistinct functions of the dual leucine zipper kinase depending on its subcellular localization
Wallbach, M., Escobar, J. D., Babaeikelishomi, R., Stahnke, M.-J., Blume, R., Schröder, S., Kruegel, J., Maedler, K., Kluth, O., Kehlenbach, R. H., et al. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.002 · Cited by 23
Optic Nerve Regeneration in Diabetic Retinopathy: Potentials and Challenges Ahead
Wu, S., & Mo, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021447 · Cited by 23
“In addition, dusp14 knockdown increases pancreatic beta-cell proliferation, which is likely to attenuate DM progression [37].”
BackgroundNakade, Y., Kitano, R., Sakamoto, K., Kimoto, S., Yamauchi, T., Inoue, T., Kobayashi, Y., Ohashi, T., Sumida, Y., Ito, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247303 · Cited by 21
Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
Vallois, D., Niederhäuser, G., Ibberson, M. R., Nagaray, V., Marselli, L., Marchetti, P., Chatton, J., & Thorens, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103277 · Cited by 21
Self-citationBosi, E., Marselli, L., Luca, C. D., Suleiman, M., Tesi, M., Ibberson, M. R., Eizirik, D. L., Cnop, M., & Marchetti, P. (2020) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaa097 · Cited by 19
Cynthia Marie-claire, A., Benturquia, N., Lundqvist, A., Courtin, C., & Noble, F. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.050 · Cited by 20
Effect of PANDER in βTC6-cell lipoapoptosis and the protective role of exendin-4
Xiang, J.-N., Chen, D., & Yang, L. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.065 · Cited by 19
β‐Cells at the crossroads: choosing between insulin granule production and proliferation
Liu, Y., Mziaut, H., Ivanova, A., & Solimena, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01107.x · Cited by 20
Bitar, M. S., & Al‐Mulla, F. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.017145 · Cited by 20
Ando, H., Gotoh, K., Fujiwara, K., Anai, M., Chiba, S., Masaki, T., Kakuma, T., & Shibata, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-05371-4 · Cited by 14
Context Sensitive Modeling of Cancer Drug Sensitivity
Chen, B., Litvin, O., Ungar, L., & Pe’er, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133850 · Cited by 16
Wei, Y., Wang, G., Wang, C., Zhou, Y., Zhang, J., & Xu, K. L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s240040 · Cited by 12
Incretin-based therapy and pancreatic beta cells
Chon, S., Riveline, J., Blondeau, B., & Gautier, J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.05.003 · Cited by 13
Phosphotyrosine Substrate Sequence Motifs for Dual Specificity Phosphatases
Zhao, B. M., Keasey, S. L., Tropea, J. E., Lountos, G. T., Dyas, B. K., Cherry, S., Raran‐Kurussi, S., Waugh, D. S., & Ulrich, R. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134984 · Cited by 14
EuroDia: a beta-cell gene expression resource
Liechti, R., Csárdi, G., Bergmann, S., Schütz, F., Sengstag, T., Boj, S. F., Servitja, J., Ferrer, J. P., Lommel, L. V., Schuit, F. C., et al. (2010) · Database · doi:10.1093/database/baq024 · Cited by 11
Self-citationThondawada, M., Wadhwani, A., Palanisamy, D., Rathore, H. S., Gupta, R. C., Chintamaneni, P. K., Samanta, M. K., Dubala, A., Varma, S. K., Krishnamurthy, P. T., et al. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1438460 · Cited by 11
Wei, G., Zhang, X., Cai, C., Sheng, J., Xu, M., Wang, C., Gu, Q., Guo, C., Chen, F., Liu, D., et al. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.840143 · Cited by 12
Sucralose activates an ERK1/2–ribosomal protein S6 signaling axis
Guerra, M. L., Kalwat, M. A., McGlynn, K., & Cobb, M. H. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12172 · Cited by 11
Rea, N., & Ramdass, P. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1579961 · Cited by 14
β-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling
Schuit, F. C., & Drucker, D. J. (2008) · Diabetes · doi:10.2337/db07-1578 · Cited by 10
“© 2008 by the American Diabetes Association.”
BackgroundInfluentialGuo, Z., Wu, Y., Zhu, L., Wang, Y., Wang, D., & Sun, X. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00908-1 · Cited by 9
Tros, F., Meirhaeghe, A., Hadjadj, S., Amouyel, P., Bougneres, P. F., & Fradin, D. (2014) · Physiological Reports · doi:10.14814/phy2.12076 · Cited by 10
Pan, Y., Shi, S., Lao, X., Zhang, J., Tan, S., Wu, Z., & Huang, J. (2016) · Peptides · doi:10.1016/j.peptides.2016.11.009 · Cited by 8
Hong, L., Ai, J., & Ma, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.091 · Cited by 7
Badejogbin, O. C., Akano, O. P., Julius, O. E. B., Agunloye, M. O., Olubiyi, M. V., Chijioke‐Agu, O. E., Obekpa, M. A., Arikawe, A. P., & Olaniyi, K. S. (2025) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12661 · Cited by 8
Exendin-4 Protects MIN6 Cells from t-BHP-Induced Apoptosis via IRE1-JNK-Caspase-3 Signaling
Chen, W.-J., Wang, L.-X., Wang, Y., Chen, Z., Liu, X., Liu, X., & Liu, L.-B. (2012) · International Journal of Endocrinology · doi:10.1155/2012/549081 · Cited by 6
“[23] demonstrated that the cAMP/protein kinase A/CREB and MAPK/ERK1/2 pathways can additively control β-cell proliferation, whereas Aikin et al.”
BackgroundPotential association between obstructive lung diseases and cognitive decline
Figat, M., Wiśniewska, A., Plichta, J., Miłkowska-Dymanowska, J., Majewski, S., Karbownik, M. S., Kuna, P., & Panek, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363373 · Cited by 7
DUSP family phosphatases in cell signaling, inflammation, and chronic diseases
Wang, C., Chuang, H., & Tan, T. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01251-0 · Cited by 4
“DUSP14 mRNA and protein levels are increased in islet β-cells of glucagon-like peptide-1 (GLP-1) − treated mice [197].”
Emerging Roles of Atypical Dual Specificity Phosphatases in Cancer
Erica, L. C., & Beeser, A. E. (2013) · InTech eBooks · doi:10.5772/54485 · Cited by 3
Dubala, A., Gupta, A., & Samanta, M. K. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.04.023 · Cited by 2
“their precursors [6–9].”
BackgroundThe binding and activation of the glucagon-like peptide-1 receptor by exendin-4
Nasr, E. M. N. (2010) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Current literature in diabetes
(2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.907
Okano, S., Sasaki, Y., Yasui, A., Kanno, S., Satoh, K., Igarashi, M., & Nakajima, O. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2741-4294
Metadata
- Authors
- Klinger, S., Poussin, C., Debril, M.-B., Dolci, W., Halban, P. A., & Thorens, B.
- Affiliations
- University of Lausanne (CH)
- University Hospital of Geneva (CH)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-03-01
- Volume
- 57
- Issue
- 3
- Pages
- 584-593
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2140883834
- Cited by
- 86
- References
- 48
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 6 · 2014: 10 · 2013: 6 · 2012: 6
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1, beta-cell proliferation, beta-cell mass, DUSP14, RGS2, CREB signaling, cAMP/protein kinase A pathway, MAPK/ERK1/2 pathway, type 1 diabetes, type 2 diabetes, islets
- MeSH terms
- Exenatide, Animals, Cell Line, Cells, Cultured, Dose-Response Relationship, Drug, Glucose, Humans, Male, Peptides, Venoms, Oligonucleotide Array Sequence Analysis, RGS Proteins, Gene Silencing, Gene Expression Profiling, Cell Proliferation, Insulin-Secreting Cells, Mice, Cyclic AMP Response Element Modulator, Glucagon-Like Peptide 1, Dual-Specificity Phosphatases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.